Dysexecutive Syndrome A Specific Pattern of Cognitive Impairment in Systemic Sclerosis PDF Print E-mail
Sunday, 07 July 2013 20:31
Systemic sclerosis (SSc), also called scleroderma, is a connective-tissue disorder characterized by obliterative microvascular lesions and diffuse interstitial fibrosis. SSc damages the small and medium-sized vessels serving the skin, joints (especially fingers and toes), and internal organs such as the lungs, gastrointestinal tract, kidneys, and heart. In most patients, neurological involvement is limited, and localized to the peripheral nervous system. Raynaud phenomenon (RP) is a prominent early vascular feature of SSc, affecting 90% of patients during their disease course and, in some, progressing
to severe ischemia.

Although the typical manifestation of neurological involvement in SSc is mononeuropathy or polyneuropathy, some imaging studies have reported cerebral hypoperfusion and acute cerebral vasculitis. Cognitive dysfunction is one of the important signs of neurological involvement in systemic lupus erythematosus, affecting up to 80% of patients. In most, the cognitive dysfunction is attributed to RP or antiphospholipid antibodies.

Although RP is a well-known feature of SSc, little is known about cognitive functioning in SSc. Limited data from small series suggest possible impairment. In our study, we aimed to evaluate cognitive functioning in patients with SSc who had no manifest sign of neurological involvement and to determine whether they showed a specific pattern of cognitive impairment that might be caused by cerebral hypoperfusion.

To continue reading the full study, please download from the link provided below.

 
More articles :

» Interleukin-6: A New Therapeutic Target in Scleroderma

Interleukin-6 (IL-6) is a classic pro-inflammatory cytokine critical in mounting an effective immune response. It is secreted by a wide array of cell types; however, its effector cells are more restricted, owing to the fact that very few cells,...

» Scleroderma and Pregnancy

In an ideal world, men and women would be able to start their families with no difficulties or problems.  However, there are many issues that can complicate matters and Scleroderma and Pregnancy is one of those issues. It is very important to...

» Survival In Pulmonary Hypertension

Stephen C. Mathai, Laura K. Hummers, Hunter C. Champion, Fredrick M. Wigley, Ari Zaiman, Paul M. Hassoun, and Reda E. GirgisARTHRITIS & RHEUMATISMVol. 60, No. 2, February 2009, pp 569–577 DOI 10.1002/art.24267 © 2009, American College of...

» Long Term Methotrexate Therapy Beneficial for Juvenile Localized Scleroderma

Researchers in Italy evaluated 65 patients with Juvenile Localized (JLS; or) previously enrolled in a double blind, randomized control trial and treated for the first 3 months with oral methotrexate (MTX; 15 mg/m2 weekly) and prednisone (1 mg/kg...

» Novel Pharmaceutical Treatment for Scleroderma Discovered

A novel pharmaceutical treatment for scleroderma, comprising the administration of miR-29, has been discovered by Steffen Gay, Oliver Distler and Britta Maurer of the Department of Rheumatology at Zurich University. Scleroderma is a chronic...

» Therapies for Scleroderma-related Pulmonary Arterial Hypertension

Paul M. HassounPosted: 08/20/2009; Expert Rev Resp Med. 2009;3(2):187-196. © 2009 Expert Reviews Ltd.Pulmonary arterial hypertension (PAH), a common complication of systemic sclerosis, carries a very severe prognosis and is one of the leading...